PE20221412A1 - Proteinas de fijacion multiespecificas para tratamiento contra el cancer - Google Patents
Proteinas de fijacion multiespecificas para tratamiento contra el cancerInfo
- Publication number
- PE20221412A1 PE20221412A1 PE2022000468A PE2022000468A PE20221412A1 PE 20221412 A1 PE20221412 A1 PE 20221412A1 PE 2022000468 A PE2022000468 A PE 2022000468A PE 2022000468 A PE2022000468 A PE 2022000468A PE 20221412 A1 PE20221412 A1 PE 20221412A1
- Authority
- PE
- Peru
- Prior art keywords
- proteins
- binding proteins
- cancer therapy
- multispecific binding
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion se refiere a proteinas de fijacion a B7H6/CD3 novedosas. La invencion tambien se refiere a acidos nucleicos que codifican tales proteinas; a metodos para preparar tales proteinas; a celulas huesped que expresan o son capaces de expresar tales proteinas; a composiciones que comprenden tales proteinas; y a usos de tales proteinas o tales composiciones, en particular, con fines terapeuticos en el campo de las enfermedades cancerosas
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19201200 | 2019-10-02 | ||
PCT/EP2020/077586 WO2021064137A2 (en) | 2019-10-02 | 2020-10-01 | Multi-specific binding proteins for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221412A1 true PE20221412A1 (es) | 2022-09-20 |
Family
ID=68136317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000468A PE20221412A1 (es) | 2019-10-02 | 2020-10-01 | Proteinas de fijacion multiespecificas para tratamiento contra el cancer |
Country Status (19)
Country | Link |
---|---|
US (2) | US11732045B2 (es) |
EP (1) | EP4038100A2 (es) |
JP (2) | JP7387885B2 (es) |
KR (1) | KR20220075383A (es) |
CN (1) | CN114641496A (es) |
AR (1) | AR120138A1 (es) |
AU (1) | AU2020358893A1 (es) |
BR (1) | BR112022004047A2 (es) |
CA (1) | CA3153372A1 (es) |
CL (1) | CL2022000664A1 (es) |
CO (1) | CO2022003552A2 (es) |
CR (1) | CR20220136A (es) |
EC (1) | ECSP22019193A (es) |
IL (1) | IL291817A (es) |
JO (1) | JOP20220079A1 (es) |
MX (1) | MX2022004042A (es) |
PE (1) | PE20221412A1 (es) |
TW (1) | TW202128756A (es) |
WO (1) | WO2021064137A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112023019138A2 (pt) | 2021-03-26 | 2023-10-24 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso |
US20220388986A1 (en) | 2021-04-29 | 2022-12-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2022258662A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a |
CN114395043B (zh) * | 2021-12-07 | 2023-07-11 | 合肥天港免疫药物有限公司 | Ncr3lg1抗体及其应用 |
CN114395045B (zh) * | 2021-12-07 | 2023-06-09 | 合肥天港免疫药物有限公司 | B7h6抗体及其应用 |
CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
WO2024089008A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024088991A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
WO2024089006A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US168A (en) | 1837-04-17 | Improvement in fire-arms | ||
US5731A (en) | 1848-08-22 | Elisha k | ||
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0658230B1 (en) | 1992-08-10 | 1996-09-25 | Alcan Aluminium Uk Limited | Fence |
DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
DK0672142T3 (da) | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
CN1268394C (zh) | 2001-01-17 | 2006-08-09 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
AU2002351896A1 (en) | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
NL1019562C2 (nl) | 2001-12-13 | 2003-06-17 | Heineken Tech Services | Klepsamenstel voor gebruik bij drankafgifte. |
US8764654B2 (en) | 2008-03-19 | 2014-07-01 | Zin Technologies, Inc. | Data acquisition for modular biometric monitoring system |
NZ566915A (en) | 2005-10-12 | 2011-09-30 | Morphosys Ag | Generation and profiling of human derived therapeutic antibodies specific for human CD38 |
CN102099055A (zh) | 2007-10-04 | 2011-06-15 | 津莫吉尼蒂克斯公司 | B7家族成员zB7H6及相关的组合物和方法 |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
FI20090280A (fi) | 2009-07-17 | 2011-01-18 | Kone Corp | Hissijärjestely ja menetelmä hissikorin liikuttamiseksi hissikuilussa |
AU2010335950B2 (en) | 2009-12-23 | 2014-08-21 | Novartis Ag | Method for decreasing immunogenicity |
RS58765B1 (sr) | 2011-05-21 | 2019-06-28 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
CN108653728B (zh) | 2011-06-23 | 2022-11-18 | 埃博灵克斯股份有限公司 | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 |
EP2987806A3 (en) | 2011-08-17 | 2016-07-13 | Glaxo Group Limited | Modified single variable domain antibodies with reduced binding to anti-drug-antibodies |
CA3182462A1 (en) | 2011-10-10 | 2013-04-18 | Xencor, Inc. | A method for purifying antibodies |
CN104395344B (zh) * | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
CN104640561A (zh) * | 2012-07-23 | 2015-05-20 | 酵活有限公司 | 包含轻链和重链的选择性配对的免疫球蛋白构建体 |
US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
WO2017181001A1 (en) | 2016-04-15 | 2017-10-19 | Trustees Of Dartmouth College | High affinity b7-h6 antibodies and antibody fragments |
MA45029B1 (fr) | 2016-05-18 | 2021-03-31 | Boehringer Ingelheim Int | Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer |
TW202016151A (zh) * | 2018-06-09 | 2020-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
-
2020
- 2020-09-30 TW TW109134076A patent/TW202128756A/zh unknown
- 2020-10-01 IL IL291817A patent/IL291817A/en unknown
- 2020-10-01 CN CN202080068909.4A patent/CN114641496A/zh active Pending
- 2020-10-01 MX MX2022004042A patent/MX2022004042A/es unknown
- 2020-10-01 AR ARP200102733A patent/AR120138A1/es unknown
- 2020-10-01 CR CR20220136A patent/CR20220136A/es unknown
- 2020-10-01 PE PE2022000468A patent/PE20221412A1/es unknown
- 2020-10-01 AU AU2020358893A patent/AU2020358893A1/en active Pending
- 2020-10-01 EP EP20789508.7A patent/EP4038100A2/en active Pending
- 2020-10-01 JP JP2022520371A patent/JP7387885B2/ja active Active
- 2020-10-01 JO JOP/2022/0079A patent/JOP20220079A1/ar unknown
- 2020-10-01 US US17/060,111 patent/US11732045B2/en active Active
- 2020-10-01 KR KR1020227014608A patent/KR20220075383A/ko unknown
- 2020-10-01 WO PCT/EP2020/077586 patent/WO2021064137A2/en active Application Filing
- 2020-10-01 CA CA3153372A patent/CA3153372A1/en active Pending
- 2020-10-01 BR BR112022004047A patent/BR112022004047A2/pt unknown
-
2022
- 2022-03-14 EC ECSENADI202219193A patent/ECSP22019193A/es unknown
- 2022-03-18 CL CL2022000664A patent/CL2022000664A1/es unknown
- 2022-03-25 CO CONC2022/0003552A patent/CO2022003552A2/es unknown
-
2023
- 2023-06-20 US US18/337,693 patent/US20230340130A1/en active Pending
- 2023-11-15 JP JP2023194494A patent/JP2024020414A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AR120138A1 (es) | 2022-02-02 |
WO2021064137A2 (en) | 2021-04-08 |
JP2024020414A (ja) | 2024-02-14 |
CO2022003552A2 (es) | 2022-04-19 |
US11732045B2 (en) | 2023-08-22 |
CR20220136A (es) | 2022-05-27 |
JOP20220079A1 (ar) | 2023-01-30 |
JP2022551081A (ja) | 2022-12-07 |
CA3153372A1 (en) | 2021-04-08 |
US20230340130A1 (en) | 2023-10-26 |
TW202128756A (zh) | 2021-08-01 |
KR20220075383A (ko) | 2022-06-08 |
EP4038100A2 (en) | 2022-08-10 |
US20210107983A1 (en) | 2021-04-15 |
WO2021064137A3 (en) | 2021-05-14 |
AU2020358893A1 (en) | 2022-03-31 |
ECSP22019193A (es) | 2022-04-29 |
JP7387885B2 (ja) | 2023-11-28 |
IL291817A (en) | 2022-06-01 |
CL2022000664A1 (es) | 2023-01-06 |
MX2022004042A (es) | 2022-05-02 |
BR112022004047A2 (pt) | 2022-05-24 |
CN114641496A (zh) | 2022-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20221412A1 (es) | Proteinas de fijacion multiespecificas para tratamiento contra el cancer | |
CO2018012374A2 (es) | Moléculas de anticuerpo para el tratamiento del cáncer | |
JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
ZA202002094B (en) | Trispecific proteins and methods of use | |
UY38242A (es) | Anticuerpos anti-cd33, anticuerpos bioespecíficos anti- cd33/anti-cd3 y usos de éstos | |
MX2020001996A (es) | Moleculas anti-cd137 y uso de estas. | |
MX2019001769A (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
BR112017010110A2 (pt) | anticorpos contra cd73 e usos do mesmo | |
PE20151180A1 (es) | Anticuerpos anti-ceacam5 y usos de estos | |
MX2017014083A (es) | Polipeptido de fusion anti-cancer. | |
MX2017014716A (es) | Polipeptido de fusion anti-cancer. | |
BR112015017800A2 (pt) | moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t | |
PH12019500312A1 (en) | T cell receptors and immune therapy using the same | |
MX2017011794A (es) | Composiciones y metodos para diagnosticos y tratamiento del cancer. | |
UY37630A (es) | Combinación farmacéutica, kit, célula huésped que la produce y su uso en métodos para el tratamiento del cáncer | |
CL2019003074A1 (es) | Variantes de la proteína bmp7 humana. | |
AR115506A1 (es) | Proteínas de fijación multiespecífica para el tratamiento del cáncer | |
WO2022236276A3 (en) | Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof | |
CO2019006926A2 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
MY195101A (en) | Novel T Cell Receptors and Immune Therapy Using the Same |